<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Masimo Corporation — News on 6ix</title>
<link>https://6ix.com/company/masimo-corporation</link>
<description>Latest news and press releases for Masimo Corporation on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 17 Feb 2026 13:02:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/masimo-corporation" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683595aa78dffbe2df1043cb.webp</url>
<title>Masimo Corporation</title>
<link>https://6ix.com/company/masimo-corporation</link>
</image>
<item>
<title>Masimo to be Acquired by Danaher for $180.00 Per Share</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-acquired-danaher-180-00-130200983</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-acquired-danaher-180-00-130200983</guid>
<pubDate>Tue, 17 Feb 2026 13:02:00 GMT</pubDate>
<description>IRVINE, Calif., February 17, 2026--Masimo Corporation (Nasdaq: MASI) ("Masimo"), a leading global medical innovator, today announced that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) ("Danaher") will acquire Masimo for $180.00 per share in cash, representing a total consideration of $9.9 billion (the "Transaction").</description>
</item>
<item>
<title>Danaher To Acquire Masimo Corporation</title>
<link>https://6ix.com/company/masimo-corporation/news/danaher-to-acquire-masimo-corporation</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/danaher-to-acquire-masimo-corporation</guid>
<pubDate>Tue, 17 Feb 2026 05:00:00 GMT</pubDate>
<description>WASHINGTON, Feb. 17, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, announced today that it has entered into</description>
</item>
<item>
<title>Masimo to Report Fourth Quarter and Full Year 2025 Financial Results after Market Close on Thursday, February 26</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-report-fourth-quarter-full-140000305</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-report-fourth-quarter-full-140000305</guid>
<pubDate>Thu, 12 Feb 2026 14:00:00 GMT</pubDate>
<description>IRVINE, Calif., February 12, 2026--Masimo (NASDAQ: MASI) will release fourth quarter and full year 2025 financial results for the period ended January 3, 2026, after the market closes on Thursday, February 26, 2026. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer.</description>
</item>
<item>
<title>Clairity Appoints Founder Dr. Connie Lehman as Chief Executive Officer; Joe Kiani Named Chairman of the Board</title>
<link>https://6ix.com/company/masimo-corporation/news/clairity-appoints-founder-dr-connie-lehman-as-chief-executive-officer-joe-kiani-named-chairman-of-the-board</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/clairity-appoints-founder-dr-connie-lehman-as-chief-executive-officer-joe-kiani-named-chairman-of-the-board</guid>
<pubDate>Wed, 21 Jan 2026 21:30:00 GMT</pubDate>
<description>BOSTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Clairity, a U.S.-based medical technology company advancing AI-powered breast cancer risk assessment, today announced that its founder, Connie Lehman, MD, PhD, has assumed the role of Chief Executive Officer as the company enters its next phase of clinical adoption and growth. The company also announced Joe Kiani as Chairman of the Board of Directors. These leadership appointments reflect a pivotal moment for Clairity following FDA De Novo authorization</description>
</item>
<item>
<title>Masimo Announces Select Preliminary 2025 Financial Results</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-announces-select-preliminary-2025-financial-results-2026-01-12</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-announces-select-preliminary-2025-financial-results-2026-01-12</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Complete fourth quarter and full-year 2025 financial results will be announced on Thursday, February 26, 2026 IRVINE, Calif.--(BUSINESS WIRE)-- Masimo</description>
</item>
<item>
<title>Masimo to Present in the J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-present-jp-morgan-2026-healthcare-conference-2026-01-07</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-present-jp-morgan-2026-healthcare-conference-2026-01-07</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced that its management will participate in the J.P. Morgan 2026 Healthcare Conference on</description>
</item>
<item>
<title>Masimo Hosts 2025 Investor Day and Details Strategic Roadmap for Durable Growth</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-hosts-2025-investor-day-and-details-strategic-roadmap-durable-growth-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-hosts-2025-investor-day-and-details-strategic-roadmap-durable-growth-2025-12</guid>
<pubDate>Wed, 03 Dec 2025 05:00:00 GMT</pubDate>
<description>Announces Long-Range Targets Including 7% - 10% Revenue CAGR Through 2028 Highlights Clear Focus on Patient Outcomes, Technology Innovation and Commercial</description>
</item>
<item>
<title>Masimo Issues Statement on California Jury Verdict Finding Patent Infringement by Apple and Awarding Masimo $634 Million in Damages</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-issues-statement-california-jury-verdict-finding-patent-infringement-apple-and</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-issues-statement-california-jury-verdict-finding-patent-infringement-apple-and</guid>
<pubDate>Fri, 14 Nov 2025 05:00:00 GMT</pubDate>
<description>IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today issued the following statement in response to the jury verdict announced in the U.S. District</description>
</item>
<item>
<title>Masimo Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-reports-third-quarter-2025-results-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-reports-third-quarter-2025-results-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>IRVINE, Calif.--(BUSINESS WIRE)-- Masimo Corporation (Nasdaq: MASI) today announced its financial results for the third quarter ended September 27, 2025.</description>
</item>
<item>
<title>Masimo to Report Third Quarter 2025 Financial Results after Market Close on Tuesday, November 4</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-report-third-quarter-2025-financial-results-after-market-close-tuesday</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-report-third-quarter-2025-financial-results-after-market-close-tuesday</guid>
<pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) will release third quarter 2025</description>
</item>
<item>
<title>Masimo to Host Investor Day on December 3, 2025</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-host-investor-day-december-3-2025-2025-10-09</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-host-investor-day-december-3-2025-2025-10-09</guid>
<pubDate>Thu, 09 Oct 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced it will host a meeting with the analyst and investor community at 9:00am PT on</description>
</item>
<item>
<title>In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones</title>
<link>https://6ix.com/company/masimo-corporation/news/feasibility-study-large-prospective-real-world-trial-masimo-setr-performed-accurately</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/feasibility-study-large-prospective-real-world-trial-masimo-setr-performed-accurately</guid>
<pubDate>Tue, 07 Oct 2025 04:00:00 GMT</pubDate>
<description>The INSPIRE Trial Prospectively Assesses Pulse Oximeter Accuracy Using a Unique Real-world Study Design and in the Feasibility Study Showed No Clinically</description>
</item>
<item>
<title>Masimo Completes Sale of Consumer Audio Business to HARMAN International</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-completes-sale-consumer-audio-business-harman-international-2025-09-23</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-completes-sale-consumer-audio-business-harman-international-2025-09-23</guid>
<pubDate>Tue, 23 Sep 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced it has completed the previously announced sale of its Sound United consumer audio</description>
</item>
<item>
<title>New Study Finds That Using Masimo Technologies to Continuously Monitor General Floor Patients Reduces Costs</title>
<link>https://6ix.com/company/masimo-corporation/news/new-study-finds-using-masimo-technologies-continuously-monitor-general-floor-patients</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/new-study-finds-using-masimo-technologies-continuously-monitor-general-floor-patients</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>Universal Surveillance Monitoring with Masimo SET® Pulse Oximetry and Patient SafetyNet™ – Repeatedly Shown to Improve Patient Outcomes and Save Lives – Also</description>
</item>
<item>
<title>Masimo Announces Expansion of Strategic Partnership with Philips</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-announces-expansion-strategic-partnership-philips-2025-09-11</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-announces-expansion-strategic-partnership-philips-2025-09-11</guid>
<pubDate>Thu, 11 Sep 2025 04:00:00 GMT</pubDate>
<description>Multi-Year Partnership Renewal with Broadened Focus Will Include Expedited Technology Adoption and Market-Based Strategic Development of Next-Generation</description>
</item>
<item>
<title>Masimo to Present in the Wells Fargo Healthcare Conference</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-present-wells-fargo-healthcare-conference-2025-08-28</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-present-wells-fargo-healthcare-conference-2025-08-28</guid>
<pubDate>Thu, 28 Aug 2025 04:00:00 GMT</pubDate>
<description>IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) today announced that its management will participate in the Wells Fargo Healthcare Conference on</description>
</item>
<item>
<title>Masimo O3® Regional Oximetry Receives FDA Clearance for Expanded Indication of Its Unique Delta Hemoglobin Parameters</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-o3r-regional-oximetry-receives-fda-clearance-expanded-indication-its-unique</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-o3r-regional-oximetry-receives-fda-clearance-expanded-indication-its-unique</guid>
<pubDate>Tue, 19 Aug 2025 04:00:00 GMT</pubDate>
<description>Now Available for Both Cerebral and Somatic Applications and for All Patient Populations, O3’s Delta Hemoglobin Parameters Offer Clinicians Additional</description>
</item>
<item>
<title>Masimo Reports Second Quarter 2025 Results</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-reports-second-quarter-2025-200500635</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-reports-second-quarter-2025-200500635</guid>
<pubDate>Tue, 05 Aug 2025 20:05:00 GMT</pubDate>
<description>IRVINE, Calif., August 05, 2025--Masimo Corporation (Nasdaq: MASI) today announced its financial results for the second quarter ended June 28, 2025.</description>
</item>
<item>
<title>Masimo to Report Second Quarter 2025 Financial Results after Market Close on Tuesday, August 5</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-report-second-quarter-2025-financial-results-after-market-close-tuesday-august</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-report-second-quarter-2025-financial-results-after-market-close-tuesday-august</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>Conference call and webcast to begin at 1:30 p.m. PT (4:30 p.m. ET) IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI) will release second quarter 2025</description>
</item>
<item>
<title>Masimo Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation</title>
<link>https://6ix.com/company/masimo-corporation/news/masimo-joins-innovators-network-american-heart-association-center-health-technology</link>
<guid isPermaLink="true">https://6ix.com/company/masimo-corporation/news/masimo-joins-innovators-network-american-heart-association-center-health-technology</guid>
<pubDate>Tue, 08 Jul 2025 04:00:00 GMT</pubDate>
<description>American Heart Association Consortium Advances Development of Evidence-based Health Tech Solutions IRVINE, Calif.--(BUSINESS WIRE)-- Masimo (NASDAQ: MASI), a</description>
</item>
</channel>
</rss>